GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (STU:6GJ) » Definitions » Net Change in Cash

Glaukos (STU:6GJ) Net Change in Cash : €-32.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Glaukos Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Glaukos's Net Change in Cash for the three months ended in Mar. 2024 was €-46.9 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was €-32.0 Mil.


Glaukos Net Change in Cash Historical Data

The historical data trend for Glaukos's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos Net Change in Cash Chart

Glaukos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.84 28.28 3.51 15.56 -25.02

Glaukos Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.28 15.87 13.23 -14.18 -46.89

Glaukos Net Change in Cash Calculation

Glaukos's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Glaukos's Net Change in Cash for the quarter that ended in Mar. 2024


Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-32.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Glaukos Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Glaukos's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.


Glaukos (STU:6GJ) Business Description

Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Glaukos (STU:6GJ) Headlines

No Headlines